{"url_path":"/sec/mnpr/8-k/2026-05-19/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ** **Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-017821-index.html","accession_number":"0001437749-26-017821","cik":"0001645469","ticker":"MNPR","issuer_name":"Monopar Therapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-017821-index.html","primary_entity_key":"0001645469","primary_entity_name":"Monopar Therapeutics"},"word_count":55,"has_tables":true,"body_markdown":"**Item 7.01.** **Regulation FD Disclosure**\n\n \n\nOn May 19, 2026, Monopar Therapeutics Inc. (“Monopar”) issued a press release announcing the presentation of results from the Phase 2 ALXN1840-WD-204 study demonstrating that ALXN1840 (tiomolibdate choline) improves copper balance in patients with Wilson disease.\n\n \n\nThe press release is furnished as Exhibit 99.1 and is incorporated herein by reference."}